Oncolytics Biotech Inc. (ONC.TO)
CAD 1.1
(-2.65%)
CAD 1.1
(-2.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -33.79 Million CAD | -18.28% |
| 2022 | -28.56 Million CAD | -8.9% |
| 2021 | -26.23 Million CAD | -3.05% |
| 2020 | -25.45 Million CAD | -23.03% |
| 2019 | -20.69 Million CAD | -24.19% |
| 2018 | -16.66 Million CAD | -6.77% |
| 2017 | -15.6 Million CAD | -2.03% |
| 2016 | -15.29 Million CAD | -9.89% |
| 2015 | -13.91 Million CAD | 26.06% |
| 2014 | -18.82 Million CAD | 21.24% |
| 2013 | -23.89 Million CAD | 34.86% |
| 2012 | -36.68 Million CAD | -27.74% |
| 2011 | -28.72 Million CAD | -43.3% |
| 2010 | -20.04 Million CAD | -17.88% |
| 2009 | -17 Million CAD | 5.9% |
| 2008 | -18.06 Million CAD | -7.27% |
| 2007 | -16.84 Million CAD | -8.71% |
| 2006 | -15.49 Million CAD | -23.67% |
| 2005 | -12.53 Million CAD | 0.81% |
| 2004 | -12.63 Million CAD | -90.87% |
| 2003 | -6.61 Million CAD | 1.97% |
| 2002 | -6.75 Million CAD | 5.41% |
| 2001 | -7.13 Million CAD | -53.63% |
| 2000 | -4.64 Million CAD | -704.62% |
| 1999 | -577.37 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.92 Million CAD | 9.24% |
| 2024 Q1 | -8.72 Million CAD | 1.39% |
| 2023 FY | -33.79 Million CAD | -18.28% |
| 2023 Q1 | -6.73 Million CAD | 17.92% |
| 2023 Q2 | -7.16 Million CAD | -6.33% |
| 2023 Q4 | -8.84 Million CAD | 19.9% |
| 2023 Q3 | -11.04 Million CAD | -54.3% |
| 2022 Q4 | -8.2 Million CAD | -35.38% |
| 2022 Q3 | -6.05 Million CAD | 13.1% |
| 2022 FY | -28.56 Million CAD | -8.9% |
| 2022 Q1 | -6.31 Million CAD | 15.36% |
| 2022 Q2 | -6.97 Million CAD | -10.51% |
| 2021 Q1 | -5.9 Million CAD | 26.9% |
| 2021 FY | -26.23 Million CAD | -3.05% |
| 2021 Q4 | -7.45 Million CAD | -21.12% |
| 2021 Q3 | -6.15 Million CAD | 8.46% |
| 2021 Q2 | -6.72 Million CAD | -13.95% |
| 2020 FY | -25.45 Million CAD | -23.03% |
| 2020 Q4 | -8.07 Million CAD | -27.81% |
| 2020 Q3 | -6.31 Million CAD | -13.85% |
| 2020 Q2 | -5.54 Million CAD | -0.45% |
| 2020 Q1 | -5.52 Million CAD | 20.45% |
| 2019 Q1 | -4.98 Million CAD | -2.16% |
| 2019 FY | -20.69 Million CAD | -24.19% |
| 2019 Q4 | -6.94 Million CAD | -101.13% |
| 2019 Q3 | -3.45 Million CAD | 34.98% |
| 2019 Q2 | -5.3 Million CAD | -6.42% |
| 2018 Q2 | -3.68 Million CAD | 21.57% |
| 2018 Q3 | -3.39 Million CAD | 7.78% |
| 2018 FY | -16.66 Million CAD | -6.77% |
| 2018 Q4 | -4.88 Million CAD | -43.73% |
| 2018 Q1 | -4.69 Million CAD | -1.29% |
| 2017 FY | -15.6 Million CAD | -2.03% |
| 2017 Q4 | -4.63 Million CAD | -52.73% |
| 2017 Q3 | -3.03 Million CAD | 30.41% |
| 2017 Q2 | -4.36 Million CAD | -22.27% |
| 2017 Q1 | -3.56 Million CAD | 31.74% |
| 2016 Q3 | -3.36 Million CAD | -28.58% |
| 2016 Q1 | -4.08 Million CAD | -15.6% |
| 2016 FY | -15.29 Million CAD | -9.89% |
| 2016 Q4 | -5.22 Million CAD | -55.38% |
| 2016 Q2 | -2.61 Million CAD | 35.97% |
| 2015 Q4 | -3.53 Million CAD | -22.71% |
| 2015 Q2 | -3.89 Million CAD | -7.91% |
| 2015 Q1 | -3.6 Million CAD | 5.33% |
| 2015 FY | -13.91 Million CAD | 26.06% |
| 2015 Q3 | -2.88 Million CAD | 26.01% |
| 2014 Q3 | -4.67 Million CAD | 1.84% |
| 2014 Q1 | -5.56 Million CAD | 5.08% |
| 2014 Q4 | -3.81 Million CAD | 18.51% |
| 2014 Q2 | -4.76 Million CAD | 14.45% |
| 2014 FY | -18.82 Million CAD | 21.24% |
| 2013 Q2 | -5.12 Million CAD | 23.3% |
| 2013 FY | -23.89 Million CAD | 34.86% |
| 2013 Q4 | -5.86 Million CAD | 5.73% |
| 2013 Q3 | -6.22 Million CAD | -21.45% |
| 2013 Q1 | -6.68 Million CAD | 21.66% |
| 2012 Q1 | -8.57 Million CAD | 26.91% |
| 2012 Q2 | -10.27 Million CAD | -19.78% |
| 2012 FY | -36.68 Million CAD | -27.74% |
| 2012 Q3 | -9.3 Million CAD | 9.45% |
| 2012 Q4 | -8.52 Million CAD | 8.33% |
| 2011 Q3 | -6.33 Million CAD | 3.32% |
| 2011 FY | -28.72 Million CAD | -43.3% |
| 2011 Q1 | -4.09 Million CAD | 45.38% |
| 2011 Q2 | -6.55 Million CAD | -59.85% |
| 2011 Q4 | -11.73 Million CAD | -85.28% |
| 2010 Q4 | -7.5 Million CAD | -86.35% |
| 2010 Q3 | -4.02 Million CAD | 7.67% |
| 2010 Q2 | -4.36 Million CAD | -5.06% |
| 2010 FY | -20.04 Million CAD | -17.88% |
| 2010 Q1 | -4.15 Million CAD | 20.6% |
| 2009 Q3 | -2.69 Million CAD | 37.83% |
| 2009 FY | -17 Million CAD | 5.9% |
| 2009 Q1 | -3.97 Million CAD | 17.31% |
| 2009 Q2 | -4.33 Million CAD | -9.15% |
| 2009 Q4 | -5.22 Million CAD | -93.82% |
| 2008 Q4 | -4.8 Million CAD | -14.17% |
| 2008 FY | -18.06 Million CAD | -7.27% |
| 2008 Q1 | -3.49 Million CAD | 33.94% |
| 2008 Q2 | -5.48 Million CAD | -56.98% |
| 2008 Q3 | -4.21 Million CAD | 23.27% |
| 2007 Q2 | -4.04 Million CAD | 7.7% |
| 2007 FY | -16.84 Million CAD | -8.71% |
| 2007 Q4 | -5.29 Million CAD | -41.29% |
| 2007 Q3 | -3.74 Million CAD | 7.52% |
| 2007 Q1 | -4.38 Million CAD | 27.91% |
| 2006 FY | -15.49 Million CAD | -23.67% |
| 2006 Q3 | -3.42 Million CAD | -14.56% |
| 2006 Q2 | -2.98 Million CAD | 0.64% |
| 2006 Q4 | -6.08 Million CAD | -77.95% |
| 2006 Q1 | -3 Million CAD | -20.68% |
| 2005 Q1 | -2.36 Million CAD | 40.79% |
| 2005 Q2 | -2.87 Million CAD | -21.58% |
| 2005 FY | -12.53 Million CAD | 0.81% |
| 2005 Q3 | -3.96 Million CAD | -38.08% |
| 2005 Q4 | -2.48 Million CAD | 37.19% |
| 2004 Q1 | -2.72 Million CAD | -41.26% |
| 2004 Q4 | -3.98 Million CAD | -40.26% |
| 2004 Q2 | -3.19 Million CAD | -17.25% |
| 2004 Q3 | -2.84 Million CAD | 10.93% |
| 2004 FY | -12.63 Million CAD | -90.87% |
| 2003 Q1 | -1.11 Million CAD | 35.05% |
| 2003 FY | -6.61 Million CAD | 1.97% |
| 2003 Q4 | -1.92 Million CAD | -5.74% |
| 2003 Q3 | -1.82 Million CAD | -1.38% |
| 2003 Q2 | -1.79 Million CAD | -61.44% |
| 2002 Q1 | -1.43 Million CAD | 14.31% |
| 2002 FY | -6.75 Million CAD | 5.41% |
| 2002 Q4 | -1.71 Million CAD | 20.61% |
| 2002 Q3 | -2.15 Million CAD | -49.86% |
| 2002 Q2 | -1.44 Million CAD | -0.41% |
| 2001 FY | -7.13 Million CAD | -53.63% |
| 2001 Q2 | -1.56 Million CAD | -24.54% |
| 2001 Q3 | -2.63 Million CAD | -67.86% |
| 2001 Q1 | -1.25 Million CAD | -47.37% |
| 2001 Q4 | -1.67 Million CAD | 36.39% |
| 2000 Q1 | -408.99 Thousand CAD | 0.0% |
| 2000 Q2 | -1.54 Million CAD | -276.56% |
| 2000 Q3 | -1.84 Million CAD | -19.59% |
| 2000 Q4 | -854.78 Thousand CAD | 53.59% |
| 2000 FY | -4.64 Million CAD | -704.62% |
| 1999 FY | -577.37 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -319.754% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 8.417% |
| Helix BioPharma Corp. | -9.37 Million CAD | -260.591% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -1134.856% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | -71.851% |
| Satellos Bioscience Inc. | -15.46 Million CAD | -118.528% |
| Sernova Corp. | -41.13 Million CAD | 17.845% |